Fisher Asset Management LLC Has $2.37 Million Holdings in OraSure Technologies, Inc. (NASDAQ:OSUR)

Fisher Asset Management LLC decreased its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 5.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 288,693 shares of the medical instruments supplier’s stock after selling 17,236 shares during the period. Fisher Asset Management LLC owned approximately 0.39% of OraSure Technologies worth $2,367,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of OSUR. Victory Capital Management Inc. raised its holdings in OraSure Technologies by 275.4% in the 4th quarter. Victory Capital Management Inc. now owns 45,881 shares of the medical instruments supplier’s stock valued at $376,000 after acquiring an additional 33,660 shares in the last quarter. Yousif Capital Management LLC increased its holdings in shares of OraSure Technologies by 40.1% during the fourth quarter. Yousif Capital Management LLC now owns 51,786 shares of the medical instruments supplier’s stock worth $425,000 after buying an additional 14,828 shares in the last quarter. Mackenzie Financial Corp bought a new position in shares of OraSure Technologies in the fourth quarter valued at approximately $229,000. Louisiana State Employees Retirement System acquired a new position in shares of OraSure Technologies in the 4th quarter worth approximately $302,000. Finally, Pacer Advisors Inc. grew its position in OraSure Technologies by 122.5% during the 4th quarter. Pacer Advisors Inc. now owns 2,403,333 shares of the medical instruments supplier’s stock worth $19,707,000 after acquiring an additional 1,323,197 shares during the last quarter. Institutional investors own 93.50% of the company’s stock.

OraSure Technologies Stock Performance

NASDAQ OSUR opened at $5.31 on Thursday. The stock has a market capitalization of $406.27 million, a P/E ratio of 7.38 and a beta of 0.23. OraSure Technologies, Inc. has a 52 week low of $4.38 and a 52 week high of $8.45. The stock has a fifty day moving average of $6.07 and a 200-day moving average of $6.80.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.09. The business had revenue of $75.88 million for the quarter, compared to analysts’ expectations of $74.13 million. OraSure Technologies had a return on equity of 14.50% and a net margin of 13.23%. The firm’s quarterly revenue was down 38.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.21 earnings per share. Equities research analysts forecast that OraSure Technologies, Inc. will post -0.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on OSUR. Evercore ISI reduced their price objective on OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating on the stock in a research note on Thursday, April 4th. StockNews.com upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Wednesday, May 1st. Two analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $6.38.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.